Please assess the completion status of the following clinical trial:

Trial Title: L-carnitine vs Placebo for the Treatment of Muscle Cramps After Imatinib in Gastrointestinal Stromal Tumors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically confirmed GIST patients who are taking imatinib~2. Age 18years or older~3. Patients experienced muscle cramps for more than 8 times (pain of NRS \> 4) or 4 times (pain of NRS \>7) within last 4 weeks~4. Life expectancy \> 6 months~5. ECOG performance status of 0-3~Exclusion Criteria:~1. Patients with renal disease receiving hemodialysis~2. Liver Cirrhosis patients with Child-Pugh class B or C~3. Patients with history of hypersensitivity to drugs including L-carnitine or nutritional supplements~4. Patients with history of spinal cord injury, peripheral vascular disease, or \> Grade 2 peripheral sensory neuropathy~5. Patients with clinically significant electrolyte imbalances such as hypocalcemia, hypokalemia, and hypomagnesaemia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- L-carnitine (Type: ACTIVE_COMPARATOR): L-carnitine 500mg three times daily (per oral)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 500mg three times daily (per oral)

Based on this trial design, predict the completion outcome and termination type (if applicable).